Reopening of Black Sea a welcome relief, but while Ukraine remains volatile, latest data shows industry adapting
28.7.2022 10:44:00 EEST | Business Wire | Press release
With news of last week’s UN deal to reopen the Black Sea, allowing ocean grain shipments to resume from Ukraine, leading real-time supply chain visibility platform FourKites® released new data showing that agile shippers are finding ways of managing the volatile situation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005468/en/
FourKites data shows increased shipments to countries bordering Russia and Ukraine (Graphic: Business Wire)
Following Friday’s grain deal between Ukraine and Russia, FourKites expects grain shipments from Black Sea ports to resume within a few days. The same deal allows Russia to export fertiliser and other products not covered by international sanctions.
“My hope is that this agreement gives big shipping companies the confidence to resume operations in the region,” says Philippe Salles, FourKites’ VP Strategic Solutions (Ocean). “The next few weeks will be telling. But if things go well, this deal could be central to averting a worldwide food crisis. And despite the latest missile attack at the port of Odessa, indicating ongoing volatility in the region, our data indicates that shippers are well prepared for any contingency.”
Ukraine typically ships millions of tonnes of grain by ocean direct from its Black Sea ports to countries including Egypt, Indonesia and Bangladesh. The war effectively closed that route, as major shipping companies concluded it was too dangerous to operate in the Black Sea. Now, it is hoped, at least some of those shipments can resume.
“Our data for the last few weeks shows that logistics operators were already adapting to the situation in Ukraine,” says Salles. “Ukrainian shippers have been shifting to road and rail to move grain to sea ports outside the country, notably in Poland or via the Balkans to Adriatic ports such as Trieste and Rijeka.”
Shipments of all types to countries bordering Russia and Ukraine remain strong compared to the rest of Europe, where the 14-day average shipment volume is up 20% compared to 21 February, when the invasion began. At the same time, less than truckload (LTL) delays to Eastern Europe have decreased over the past few weeks, with delayed LTL shipments now only 15% higher than when the conflict began. This is down 48% month-on-month compared to mid-June, when LTL delays were as much as 33% higher than when the conflict began.
Prior to the UN deal, hundreds of thousands of tonnes of grain were destined to travel by longer land routes, which raised questions about whether there would be sufficient capacity to provide the thousands of additional truck journeys that would be needed.
“Ukrainian carriers are going full throttle to export grain and revive the country’s economic growth,” comments Maciej Mackowiak, FourKites’ Director, Carrier Marketing, Europe, who is based in Poland. “We are already seeing a lot of congestion on the Polish/Ukraine border because, since mid-July, the European Union has allowed Ukrainian road transport companies to make shipments without permits.”
Overall, moving goods into or out of Ukraine remains difficult. Shipment volumes to Ukraine have recovered slightly from their nadir in March, but are still 65% down on pre-war levels.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005468/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
